This article contains links to products or services from one or more of our advertisers or partners. We may receive a commission when you click or make a purchase using our site. Learn more about how we make money.

How to buy FibroGen stock | $43.08

Own FibroGen stock in just a few minutes.


Fact checked

FibroGen, Inc is a biotechnology business based in the US. FibroGen shares (FGEN) are listed on the NASDAQ and all prices are listed in US Dollars. FibroGen employs 531 staff and has a trailing 12-month revenue of around USD$108.4 million.

How to buy shares in FibroGen

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for FibroGen. Find the stock by name or ticker symbol: FGEN. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until FibroGen reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$43.08, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of FibroGen, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of FibroGen. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

FibroGen share price

Use our graph to track the performance of FGEN stocks over time.

FibroGen shares at a glance

Information last updated 2020-10-20.
Latest market close USD$43.08
52-week range USD$22.65 - USD$49.7
50-day moving average USD$44.1229
200-day moving average USD$40.7214
Wall St. target price USD$62.75
PE ratio 85.0431
Dividend yield N/A (0%)
Earnings per share (TTM) USD$0.464

Buy FibroGen shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Stocks, Mutual funds, ETFs, Forex
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy FibroGen stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

FibroGen price performance over time

Historical closes compared with the close of $43.08 from 2020-11-16

1 week (2020-11-25) 7.65%
1 month (2020-11-06) 4.36%
3 months (2020-09-04) -0.23%
6 months (2020-06-05) 31.99%
1 year (2019-12-05) -8.61%
2 years (2018-12-04) 4.21%
3 years (2017-12-05) -3.08%
5 years (2015-12-04) 41.85%

Is FibroGen under- or over-valued?

Valuing FibroGen stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of FibroGen's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

FibroGen's P/E ratio

FibroGen's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 85x. In other words, FibroGen shares trade at around 85x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

FibroGen's EBITDA

FibroGen's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$49.3 million.

The EBITDA is a measure of a FibroGen's overall financial performance and is widely used to measure a its profitability.

FibroGen financials

Revenue TTM USD$108.4 million
Gross profit TTM USD$46.2 million
Return on assets TTM -23.18%
Return on equity TTM -58.53%
Profit margin -287.01%
Book value $4.387
Market capitalisation USD$4.1 billion

TTM: trailing 12 months

Shorting FibroGen shares

There are currently 7.6 million FibroGen shares held short by investors – that's known as FibroGen's "short interest". This figure is 9.8% up from 6.9 million last month.

There are a few different ways that this level of interest in shorting FibroGen shares can be evaluated.

FibroGen's "short interest ratio" (SIR)

FibroGen's "short interest ratio" (SIR) is the quantity of FibroGen shares currently shorted divided by the average quantity of FibroGen shares traded daily (recently around 956620.9331652). FibroGen's SIR currently stands at 7.93. In other words for every 100,000 FibroGen shares traded daily on the market, roughly 7930 shares are currently held short.

However FibroGen's short interest can also be evaluated against the total number of FibroGen shares, or, against the total number of tradable FibroGen shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case FibroGen's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 FibroGen shares in existence, roughly 80 shares are currently held short) or 0.0961% of the tradable shares (for every 100,000 tradable FibroGen shares, roughly 96 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against FibroGen.

Find out more about how you can short FibroGen stock.

FibroGen share dividends

We're not expecting FibroGen to pay a dividend over the next 12 months.

FibroGen share price volatility

Over the last 12 months, FibroGen's shares have ranged in value from as little as $22.65 up to $49.7. A popular way to gauge a stock's volatility is its "beta".

FGEN.US volatility(beta: 1.62)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while FibroGen's is 1.6161. This would suggest that FibroGen's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

FibroGen overview

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. The company is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase II trial for the treatment of Duchenne muscular dystrophy. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site